FI961202A - Grb3-3-geeni, sen variantteja ja niiden käyttöjä - Google Patents

Grb3-3-geeni, sen variantteja ja niiden käyttöjä Download PDF

Info

Publication number
FI961202A
FI961202A FI961202A FI961202A FI961202A FI 961202 A FI961202 A FI 961202A FI 961202 A FI961202 A FI 961202A FI 961202 A FI961202 A FI 961202A FI 961202 A FI961202 A FI 961202A
Authority
FI
Finland
Prior art keywords
grb3
variants
gene
protein
sequences
Prior art date
Application number
FI961202A
Other languages
English (en)
Swedish (sv)
Other versions
FI961202A0 (fi
FI120499B (fi
Inventor
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI961202A0 publication Critical patent/FI961202A0/fi
Publication of FI961202A publication Critical patent/FI961202A/fi
Application granted granted Critical
Publication of FI120499B publication Critical patent/FI120499B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
FI961202A 1993-09-15 1996-03-14 Menetelmiä, jotka liittyvät Grb3-3-geeniin tai sen variantteihin FI120499B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9310971 1993-09-15
FR9310971A FR2710074B1 (fr) 1993-09-15 1993-09-15 Gène GRB3-3, ses variants et leurs utilisations.
FR9400542 1994-05-09
PCT/FR1994/000542 WO1995007981A1 (fr) 1993-09-15 1994-05-09 Gene grb3-3, ses variants et leurs utilisations

Publications (3)

Publication Number Publication Date
FI961202A0 FI961202A0 (fi) 1996-03-14
FI961202A true FI961202A (fi) 1996-03-14
FI120499B FI120499B (fi) 2009-11-13

Family

ID=9450882

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961202A FI120499B (fi) 1993-09-15 1996-03-14 Menetelmiä, jotka liittyvät Grb3-3-geeniin tai sen variantteihin

Country Status (27)

Country Link
US (2) US5831048A (fi)
EP (1) EP0719328B1 (fi)
JP (1) JP3794697B2 (fi)
KR (1) KR100330477B1 (fi)
CN (1) CN1098930C (fi)
AT (1) ATE196926T1 (fi)
AU (1) AU698819B2 (fi)
BR (1) BR9407693A (fi)
CA (1) CA2169938A1 (fi)
CZ (1) CZ288882B6 (fi)
DE (1) DE69426121T2 (fi)
DK (1) DK0719328T3 (fi)
ES (1) ES2152313T3 (fi)
FI (1) FI120499B (fi)
FR (1) FR2710074B1 (fi)
GR (1) GR3034600T3 (fi)
HU (1) HU221516B (fi)
IL (2) IL110942A (fi)
NO (1) NO319144B1 (fi)
NZ (1) NZ266162A (fi)
PL (1) PL178402B1 (fi)
PT (1) PT719328E (fi)
RU (1) RU2159815C2 (fi)
SK (1) SK281123B6 (fi)
UA (1) UA46715C2 (fi)
WO (1) WO1995007981A1 (fi)
ZA (1) ZA947059B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US6171800B1 (en) 1995-06-07 2001-01-09 Biogen, Inc. Method of making and binding CAIP polypeptides
US5837844A (en) * 1995-06-07 1998-11-17 Biogen, Inc. CAIP-like gene family
US6423824B1 (en) 1995-06-07 2002-07-23 Biogen, Inc. CAIP-like gene family
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997049808A1 (en) * 1996-06-27 1997-12-31 Biogen, Inc. The caip-like gene family
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
KR101215789B1 (ko) 2000-03-30 2012-12-26 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
EP1460898A4 (en) * 2002-01-03 2006-05-24 Univ Texas OLIGONUCLEOTIDES ANTISENSE WT1 INHIBITING BREAST CANCER

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3462498B2 (ja) * 1991-01-18 2003-11-05 ニューヨーク・ユニバーシティ レセプターチロシンキナーゼ標的タンパク質のｃＤＮＡクローニング方法及びｈＧＲＢタンパク質
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof

Also Published As

Publication number Publication date
IL126756A (en) 2006-06-11
NO960965D0 (no) 1996-03-08
HU221516B (hu) 2002-11-28
GR3034600T3 (en) 2001-01-31
UA46715C2 (uk) 2002-06-17
AU6724794A (en) 1995-04-03
CN1133064A (zh) 1996-10-09
EP0719328B1 (fr) 2000-10-11
PL178402B1 (pl) 2000-04-28
NZ266162A (en) 1997-11-24
IL110942A (en) 2001-12-23
FI961202A0 (fi) 1996-03-14
PL313445A1 (en) 1996-07-08
JPH09502357A (ja) 1997-03-11
CZ288882B6 (cs) 2001-09-12
SK281123B6 (sk) 2000-12-11
CZ75896A3 (en) 1996-06-12
FR2710074A1 (fr) 1995-03-24
JP3794697B2 (ja) 2006-07-05
DE69426121T2 (de) 2001-05-31
HU9600668D0 (en) 1996-05-28
DK0719328T3 (da) 2000-11-13
US5831048A (en) 1998-11-03
ATE196926T1 (de) 2000-10-15
AU698819B2 (en) 1998-11-05
DE69426121D1 (de) 2000-11-16
FI120499B (fi) 2009-11-13
EP0719328A1 (fr) 1996-07-03
BR9407693A (pt) 1997-02-04
IL110942A0 (en) 1994-11-28
CA2169938A1 (fr) 1995-03-23
NO319144B1 (no) 2005-06-27
WO1995007981A1 (fr) 1995-03-23
ES2152313T3 (es) 2001-02-01
ZA947059B (en) 1995-05-18
USRE37952E1 (en) 2002-12-31
HUT74273A (en) 1996-11-28
SK34596A3 (en) 1996-07-03
RU2159815C2 (ru) 2000-11-27
PT719328E (pt) 2001-02-28
KR100330477B1 (ko) 2002-12-02
NO960965L (no) 1996-03-08
FR2710074B1 (fr) 1995-12-08
CN1098930C (zh) 2003-01-15

Similar Documents

Publication Publication Date Title
ES2105698T3 (es) Oligonucleotidos modificados con 7-deazapurina.
FI962247A (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DK289688D0 (da) Ekspression af proapolipoprotein a-i.
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
FI961202A (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
DK0981630T3 (da) Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
ZA933216B (en) Recombinant DNA molecules encoding aminopeptidas enzymes and their use in the preparation of vaccines against helminth infections
ATE384787T1 (de) Tripeptidyl-aminopeptidase
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DE69321720T2 (de) Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen
ATE215123T1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
EA199900893A1 (ru) Бактериальные плазмиды
ZA982009B (en) Isolated nucleic acid molecules encoding SSX family members and uses thereof.
DK1032683T3 (da) Polypeptider med 5-aminolevulinsyre-syntase-aktivitet og nukleinsyrer, der koder for disse
DK1196607T3 (da) Antibakterielt chlamysin B-protein, gen kodende derfor samt ekspressionssystem

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS PHARMA S.A.

FG Patent granted

Ref document number: 120499

Country of ref document: FI